← 返回

替沙仑赛在儿童复发/难治性 B 细胞急性淋巴细胞白血病中的感染相关不良事件:一项 FAERS 药物警戒研究

英文原题:Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study.

查看英文原题

Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study.

PubMed 2026/08/07(内容时间) Children (Basel) Q1 · IF 2.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

Tisagenlecleucel(tis-cel)是唯一获批用于儿童/青少年复发/难治性B细胞急性淋巴细胞白血病(r/r B-ALL)的CAR-T 细胞疗法。感染相关不良事件(IRAEs)是非复发死亡的主要原因,但针对<18岁患者的专门分析仍然有限。

本研究旨在基于FDA不良事件报告系统(FAERS)数据库,分析接受tis-cel治疗的儿童和青少年r/r B-ALL患者中IRAEs的特征。分析内容包括报告比例、时间分布、病原谱以及与其他不良事件的重叠特征,为<18岁患者的感染预防和控制提供假设。 研究设计与方法:我们分析了FAERS数据(2017年8月至2025年3月),纳入492例接受tis-cel治疗的<18岁r/r B-ALL患者病例。对149份感染相关报告进行了不成比例分析(报告比值比,ROR;信息成分,IC)、发病时间分析及共现评估。

感染相关AEs发生于30.28%的病例中,感染患者的死亡率显著高于非感染患者(40.27% vs. 12.83%,p < 0.001)。大多数感染(93.86%)发生于一个月内(中位发病时间 = 4天),在15天内达到高峰(77.50%);2.65%发生于一年后。观察到艰难梭菌(ROR 025 = 5.45)、流感病毒(ROR 025 = 7.16)和腺病毒(ROR 025 = 3.51)具有显著的不成比例报告信号。低丙种球蛋白血症(52.94%)和缺氧(54.90%)与感染的共现率高于CAR-T 特异性毒性(23.08-35.41%)。

tis-cel 治疗后感染相关 AE 在儿童和青少年 r/r B-ALL 患者中较为常见,且与死亡率显著升高相关。虽然大多数发生于早期,但晚期感染仍需长期警惕。不成比例分析识别出提示潜在高风险病原体的信号,如艰难梭菌、流感和腺病毒,而低丙种球蛋白血症/缺氧可能作为早期预警指标。这些产生假设的发现需要在前瞻性研究中加以验证。

展开英文摘要原文

Background : Tisagenlecleucel (tis-cel) is the sole chimeric antigen receptor T-cell (CAR-T) therapy approved for pediatric/adolescent relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Infection-related adverse events (IRAEs) represent a leading cause of non-relapse mortality, yet dedicated analysis in patients <18 years remains limited. Objective : This study aimed to analyze the characteristics of IRAEs in pediatric and adolescent patients with r/r B-ALL treated with tis-cel, based on the FDA Adverse Event Reporting System (FAERS) database. The analysis included the reporting proportion, temporal distribution, pathogen spectrum, and overlapping features with other adverse events, generate hypotheses for infection prevention and control in patients aged <18 years. Research Design and Methods : We analyzed FAERS data (August 2017-March 2025) and included 492 cases of <18-year-old r/r B-ALL patients treated with tis-cel. Disproportionality analyses (reporting odds ratio, ROR; information component, IC), time-to-onset analysis, and co-occurrence assessments were performed on 149 infection-related reports. Results : Infection-related AEs occurred in 30.

28% of cases, with significantly higher mortality in infected versus non-infected patients (40. 27% vs. 12. 83%, p < 0. 001). Most infections (93. 86%) occurred within one month (median time-to-onset = 4 days), peaking within 15 days (77. 50%); 2. 65% occurred after one year. Significant disproportionate reporting signals were observed for Clostridioides difficile (ROR 025 = 5. 45), influenza virus (ROR 025 = 7. 16), and adenovirus (ROR 025 = 3. 51). Hypogammaglobulinemia (52. 94%) and hypoxia (54. 90%) exhibited higher co-occurrence with infections than CAR-T-specific toxicities (23.

08-35. 41%). Conclusions : Infection-related AEs following tis-cel treatment are frequent and associated with significantly increased mortality in pediatric and adolescent r/r B-ALL patients. While most occur early, late infections warrant long-term vigilance.

Disproportionality analyses identified signals suggestive of potential high-risk pathogens such as Clostridioides difficile,, influenza, and adenovirus, and hypogammaglobulinemia/hypoxia may serve as early warning indicators. These hypothesis-generating findings require validation in prospective studies.

论文信息

作者
Song X、Liu Y、Qiao X
单位
Department of Pediatrics, Tongji Hospital, Tongji University School of Medicine, 389 Xincun Road, Shanghai 200065, China.China
期刊
Children (Basel, Switzerland)2026 Aug 7
原文标识
PubMed 42650392 · DOI 10.3390/children13081054